MedTrace Logo

First Line Osimertinib in the Real World: an Inter-regional Prospective Study

NCT04965701 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-11-13

No results posted yet for this study

Summary

This study (FLOWER) will investigate effectiveness, safety, progression patterns and clinical management of untreated advanced NSCLC patients receiving fist-line osimertinib in the real-world.

Conditions

  • EGF-R Positive Non-Small Cell Lung Cancer

Interventions

DRUG

Osimertinib 80 MG

Osimertinib is administered according to clinical practice at the recommended dose of 80 mg, orally, once a day.

Sponsors & Collaborators

  • Istituto Oncologico Veneto IRCCS

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2022-06-01
Completion
2023-05-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04965701 on ClinicalTrials.gov